Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Lane Hall-Witt who wrote (79803)	1/20/2000 1:02:00 PM
From: blackmerlin	Read Replies (1) \| Respond to of 120523

BTGC: Rated a buy today and "trades at a substantial discount to other profitable biotech." Sound like a good biotech pick-see below: "NEW YORK, Jan 20 (Reuters) - Warburg Dillon Read on Thursday said analyst Michael Wood initiated coverage of Bio-Technology General Corp. (NasdaqNM:BTGC - news) with a buy. -- said company has $700 million market cap and trades at a ``substantial' discount to other profitable biotechs. -- sees EPS growth of about 20 percent over next five years. -- set price target of $18.50. -- said firm has five products on market, with two biggest expected to drive most of firm's earnings growth over next two years. -- Shares rose about 1/2 to 15-11/16 in Nasdaq trade early on Thursday." Good luck, Jake Blackmerlin